Skip to Content
Stock Analyst Update

Regeneron Authorized to Use Antibody Cocktail

We're maintaining our $500 fair value estimate for the narrow-moat drug manufacturer.


Regeneron's (REGN) antibody cocktail REGN-COV2 (casirivimab and imdevimab) received emergency use authorization from the U.S. Food and Drug Administration on Nov. 21, targeted at COVID-19 patients who are not yet hospitalized but are considered high risk. Regeneron gave the first glimpse of data on REGN-COV2 in September with more details in October, showing a promising ability to lower viral loads and reduce rates of hospitalization. Based on reduced potential for the cocktail to serve the sickest hospitalized patients, a lower assumed price, as well as continued progress with several vaccine programs, we've reduced our estimates for sales of the cocktail, and we include $1.7 billion in 2021 sales for REGN-COV2 in our Regeneron model ($3.4 billion in potential global sales in 2021, shared with Roche).

However, this did not have a significant impact on our $500 fair value estimate for Regeneron. Overall, we think demand will exceed supply over the next few months, but that long-term demand (late 2021 and into 2022) will depend on REGN-COV2's success in continuing trials in hospitalized patients as well as in prevention studies, as well as data from competing antibody programs and other treatment regimens. The success of REGN-COV2 supports the continued promise of Regeneron's antibody technology, which underpins a narrow moat and positive moat trend rating.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.